Author:
Chen Hua-Jun,Mok Tony S.,Chen Zhi-Hong,Guo Ai-Lin,Zhang Xu-Chao,Su Jian,Wu Yi-Long
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine
Reference27 articles.
1. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
2. Pao W, Balak MN, Riely GJ et al (2006) Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. J Clin Oncol 24(Suppl):383s abstract 7078
3. Kwak EL, Sordella R, Bell DW et al (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665–7670
4. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792
5. Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070–2075
Cited by
97 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献